Medicine and Dentistry
Epidermal Growth Factor Receptor
100%
Cells
62%
Neoplasm
37%
Therapeutic Procedure
25%
Cell Line
25%
Gefitinib
25%
Epidermal Growth Factor Receptor Kinase Inhibitor
25%
Multiplex Ligation Dependent Probe Amplification
25%
Patient
12%
Development
12%
Analysis
12%
down Regulation
12%
Tumor Suppressor Gene
12%
Drug Sensitivity
12%
Malignant Pleural Effusion
12%
Osimertinib
12%
Biochemistry, Genetics and Molecular Biology
Mutation
62%
Gefitinib
25%
Receptor Tyrosine Kinase Inhibitors
25%
Multiplex Ligation-Dependent Probe Amplification
25%
Sample
12%
Development
12%
down Regulation
12%
Drug Sensitivity
12%
LC50
12%
TSC1
12%
Engineering
Mechanisms
37%
Losses
37%
Development
12%
Events
12%
Activation
12%
Suppressor
12%
Ports and Harbors
12%
Signaling Downstream
12%
Copy Number
12%
Downregulation
12%
Neuroscience
Epidermal Growth Factor Receptor
25%
Receptor Tyrosine Kinase Inhibitors
25%
Gefitinib
25%
Multiplex Ligation-Dependent Probe Amplification
25%
TSC1
12%
Osimertinib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
37%
Epidermal Growth Factor Receptor Kinase Inhibitor
25%
Gefitinib
25%
Malignant Pleura Effusion
12%
Osimertinib
12%